Sofosbuvir Is Waiting for Green Light | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

VA Model Improves Hep C Care

Back to News Homepage
Next

Are Saunas Recommended for Hepatitis C?

Sofosbuvir Is Waiting for Green Light

The Editors at Hepatitis Central
February 26, 2013

Print this page

Gilead’s sofosbuvir is on the cusp of achieving a preliminary stamp of approval as the first interferon-free treatment for Hepatitis C.
Sofosbuvir Is Waiting for Green Light Pin it on Pinterest

Regulators Await Gilead’s Hep C Candidate

Feb 21 2013

Gilead Sciences’ (GILD) sofosbuvir has passed all its preliminary examinations, and now is looking like a good bet for regulatory submissions in the coming months. The last of four phase III trials in combination with one or both of the mainstays of current hepatitis C treatment has met its primary endpoint, likely providing sufficient data to support approval in combination therapy in the six major genotypes of the virus.

The pivotal data leave the California company tantalisingly close to reaching the holy grail of hep C treatment: an all-oral treatment that removes interferon and ribavirin – and their associated side effects – from the treatment regimen. With filing of the fixed-dose combination with GS-5885 not expected until next year, a limited approval of sofosbuvir should help Gilead begin to earn back the $11bn it spent to acquire the candidate.

Continue reading this entire article:
http://seekingalpha.com/article/1213061-regulators-await-gilead-s-hep-c-candidate?source=google_news

28 Comments
Share
Share
Previous

VA Model Improves Hep C Care

Back to News Homepage
Next

Are Saunas Recommended for Hepatitis C?

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.